KPTI

Karyopharm Therapeutics (KPTI) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov^[4], including 4 Phase 3^[1], 6 Phase 2^[2], 1 Phase 1^[3].

Trial NCT04562389^[5] evaluates Selinexor in Myelofibrosis with a target enrollment of 353 participants. Trial NCT05611931^[6] evaluates Selinexor in Endometrial Cancer with a target enrollment of 276 participants. Trial NCT03555422^[7] evaluates Selinexor in Endometrial Cancer with a target enrollment of 263 participants.

No Form 4 insider filings for KPTI were recorded at the SEC in the past 30 days^[8].